These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 32007931)

  • 21. Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy: results from the ICEBIO registry.
    Palsson O; Love TJ; Wallman JK; Kapetanovic MC; Gunnarsson PS; Gudbjornsson B
    Scand J Rheumatol; 2024 Jun; ():1-7. PubMed ID: 38832494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis.
    Meyer A; Chatelus E; Wendling D; Berthelot JM; Dernis E; Houvenagel E; Morel J; Richer O; Schaeverbeke T; Gottenberg JE; Sibilia J;
    Arthritis Rheum; 2011 May; 63(5):1274-80. PubMed ID: 21538314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.
    Glintborg B; Gudbjornsson B; Krogh NS; Omerovic E; Manilo N; Holland-Fischer M; Lindegaard HM; Loft AG; Nordin H; Johnsen L; Oeftiger SF; Hansen A; Rasmussen C; Grondal G; Geirsson AJ; Hetland ML
    Rheumatology (Oxford); 2014 Nov; 53(11):2100-9. PubMed ID: 24939677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The majority of patients with psoriatic arthritis are not eligible for randomised clinical trials.
    Runarsdottir EE; Gunnarsdottir AI; Love TJ; Gunnarsson PS; Gudbjornsson B;
    Clin Exp Rheumatol; 2018; 36(6):1068-1073. PubMed ID: 29998835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.
    Rotar Z; Hočevar A; Rebolj Kodre A; Praprotnik S; Tomšič M;
    Clin Rheumatol; 2015 Oct; 34(10):1787-93. PubMed ID: 26345633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis.
    Mori Y; Kuwahara Y; Chiba S; Itoi E
    Mod Rheumatol; 2015 May; 25(3):431-4. PubMed ID: 25295919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
    Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
    Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register.
    Vieira-Sousa E; Eusébio M; Ávila-Ribeiro P; Khmelinskii N; Cruz-Machado R; Rocha TM; Bernardes M; Santos-Faria D; Silva JL; Santos H; Miguel C; Carvalho P; Costa T; Duarte AC; Meirinhos T; Nero P; Fonseca JE; Santos MJ
    J Rheumatol; 2020 May; 47(5):690-700. PubMed ID: 31371659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
    Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
    Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.